Compare Abeona Therapeutics Inc (ABEO) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.69. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | FEPI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $49.54 |
52-Week Low | $4.17 | $38.13 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $42.53, up 1.5% with a bearish technical signal. The ETF employs a covered call strategy on concentrated tech holdings, generating high weekly dividends but facing NAV erosion concerns. Recent transition to weekly distributions aims to enhance income appeal, though technical indicators show selling pressure outweighing buying signals.
The outlook balances high yield appeal against structural limitations. The 25% dividend yield attracts income seekers, but the covered call strategy caps upside potential during tech rallies. Key risks include concentrated exposure to volatile AI/mega-cap stocks and persistent NAV erosion, requiring careful risk-reward assessment for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
